Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
Submitted Date
Received Date
Accepted Date
Issued Date
2024-01-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
14737140
eISSN
17448328
Scopus ID
2-s2.0-85204599478
WOS ID
Pubmed ID
39275993
arXiv ID
Call No.
Other identifier(s)
Journal Title
Expert Review of Anticancer Therapy
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Expert Review of Anticancer Therapy (2024)
Citation
Miller C.D., Likasitwatanakul P., Toye E., Hwang J.H., Antonarakis E.S. (2024). Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment. Retrieved from: https://hdl.handle.net/20.500.14594/101428.
Title
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
Introduction: Prostate cancer continues to be a major cause of morbidity and mortality for men worldwide. Enzalutamide, a second-generation non-steroidal antiandrogen that blocks androgen receptor (AR) transcriptional activity, is a treatment for biochemically recurrent, metastatic, castration-sensitive, and castration-resistant tumors. Unfortunately, most patients ultimately develop resistance to enzalutamide, making long-term treatment with this agent challenging. Areas covered: We performed a literature search of PubMed without date restrictions to investigate the literature surrounding enzalutamide and discuss the current uses of enzalutamide, proposed mechanisms driving resistance, and summarize current efforts to mitigate this resistance. Expert opinion: Enzalutamide is an effective prostate cancer therapy that is currently used in biochemically recurrent and metastatic disease and for both castration-sensitive and castration-resistant tumors. Unfortunately, resistance to enzalutamide occurs in each of these scenarios. In the clinical setting, enzalutamide-resistant tumors are either AR-driven or AR-indifferent. AR-dependent resistance mechanisms include genomic or epigenomic events that result in enhanced AR signaling. Tumors that do not require AR signaling instead may depend on alternative oncogenic pathways. There are numerous strategies to mitigate enzalutamide resistance, including concurrent use of PARP inhibitors or immune therapies. Additional work is required to uncover novel approaches to treat patients in the enzalutamide-resistant setting.